(Reuters) – Merck & Co Inc said on Wednesday that the
expected a broad about its drug study data for
Zetia cholesterol will be available in 2014 instead of the
2013.
essay on 18,000 patients, closely followed and
called IMPROVE-IT, it was designed to assess whether combining Zetia
with the oldest of so-called Merck cholesterol drug
Zocor is more effective in reducing heart attacks and
strokes (CVA) than Zocor alone.
Zocor, known generically as simvastatin, is one
similar to Lipitor from Pfizer Inc. Zetia Statin reduces the
cholesterol using a method different. Merck Vytorin combines
both drugs in a single pill, and is the product that is
you are evaluating in the trial.
the questions about combination therapy came
then of that data on a prior trial, known as ENHANCE
they thrown that Vytorin was no more effective at reducing plaque
in the carotid artery that Zocor only and not respond the
question about whether adding Zetia more decreased the rate of heart attacks.
and while Vytorin Yes appeared better in decreasing of the
’bad’ LDL cholesterol, did not generate major changes in other
key measurements in patients with a hereditary form of
high cholesterol known as hypercholesterolemia family.
is stipulated that the IMPROVE-IT trial ends once that
5,250 episodes clinical, as attacks have reported
cardiac or LCA.
in March of this year, driver Security Committee of
trial, an independent, entity data completed a second
preliminary efficacy analysis and recommended not to change the design
of the Studie. und sagte, dass er plante, überprüfen Sie die Daten wieder in
etwa neun Monate.
Merck darauf hingewiesen, dass die Revision nun auf verschoben hatte
März von 2013. basierend auf der aktuellen Rate, bei der sich
Episoden, Unterrichtung, die Firma sagte, es erwartet, dass die Anzahl
Ziel wird im Jahr 2014 erreicht werden.